Cognitive Efficacy of Quetiapine in Early-Onset First-Episode Psychosis: A 12-Week Open Label Trial

Twenty-three adolescents with psychotic disorders, aged from 13 to 18years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's≤0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P=0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (>300mg/day or <300mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P=0.048), inhibition abilities (P=0.038) and positive symptoms (P=0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptom

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

The original version of this article unfortunately contained a mistake

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Cognitive efficacy of quetiapine in early-onset first-episode psychosis: a 12-week open label trial.

Twenty-three adolescents with psychotic disorders, aged from 13 to 18 years, participated in a 12-week open label trial (17 adolescents completed the study) in order to examine the impact of quetiapine on clinical status and cognitive functions (encompassing processing speed, attention, short-term memory, long-term memory and executive function). An improvement in Clinical Global Impression and Positive and Negative Symptom Scale (P's ≤ 0.001) was observed. In addition, after controlling for amelioration of symptoms, a significant improvement was observed on one executive function (P = 0.044; Trail Making Part B). The remaining cognitive abilities showed stability. In addition, we observed an interaction between quetiapine doses (&gt;300 mg/day or &lt;300 mg/day) and time, where lower doses showed more improvement in verbal short-term memory (P = 0.048), inhibition abilities (P = 0.038) and positive symptoms (P = 0.020). The neuropsychological functioning of adolescents with psychotic disorders remained mainly stable after 12 weeks of treatment with quetiapine. However, lower doses seemed to have a better impact on two components of cognition (inhibition abilities and verbal short-term memory) and on positive symptoms

Tunneling Nanotubes and Gap Junctions-Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions.

Cell-to-cell communication is essential for the organization, coordination, and development of cellular networks and multi-cellular systems. Intercellular communication is mediated by soluble factors (including growth factors, neurotransmitters, and cytokines/chemokines), gap junctions, exosomes and recently described tunneling nanotubes (TNTs). It is unknown whether a combination of these communication mechanisms such as TNTs and gap junctions may be important, but further research is required. TNTs are long cytoplasmic bridges that enable long-range, directed communication between connected cells. The proposed functions of TNTs are diverse and not well understood but have been shown to include the cell-to-cell transfer of vesicles, organelles, electrical stimuli and small molecules. However, the exact role of TNTs and gap junctions for intercellular communication and their impact on disease is still uncertain and thus, the subject of much debate. The combined data from numerous laboratories indicate that some TNT mediate a long-range gap junctional communication to coordinate metabolism and signaling, in relation to infectious, genetic, metabolic, cancer, and age-related diseases. This review aims to describe the current knowledge, challenges and future perspectives to characterize and explore this new intercellular communication system and to design TNT-based therapeutic strategies

Tunneling Nanotubes and Gap Junctions-Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions

textabstractCell-to-cell communication is essential for the organization, coordination, and development of cellular networks and multi-cellular systems. Intercellular communication is mediated by soluble factors (including growth factors, neurotransmitters, and cytokines/chemokines), gap junctions, exosomes and recently described tunneling nanotubes (TNTs). It is unknown whether a combination of these communication mechanisms such as TNTs and gap junctions may be important, but further research is required. TNTs are long cytoplasmic bridges that enable long-range, directed communication between connected cells. The proposed functions of TNTs are diverse and not well understood but have been shown to include the cell-to-cell transfer of vesicles, organelles, electrical stimuli and small molecules. However, the exact role of TNTs and gap junctions for intercellular communication and their impact on disease is still uncertain and thus, the subject of much debate. The combined data from numerous laboratories indicate that some TNT mediate a long-range gap junctional communication to coordinate metabolism and signaling, in relation to infectious, genetic, metabolic, cancer, and age-related diseases. This review aims to describe the current knowledge, challenges and future perspectives to characterize and explore this new intercellular communication system and to design TNT-based therapeutic strategies

Detecting and Studying High-Energy Collider Neutrinos with FASER at the LHC

Neutrinos are copiously produced at particle colliders, but no collider neutrino has ever been detected. Colliders produce both neutrinos and anti-neutrinos of all flavors at very high energies, and they are therefore highly complementary to those from other sources. FASER, the Forward Search Experiment at the LHC, is ideally located to provide the first detection and study of collider neutrinos. We investigate the prospects for neutrino studies with FASER$\nu$, a proposed component of FASER, consisting of emulsion films interleaved with tungsten plates with a total target mass of 1.2 t, to be placed on-axis at the front of FASER. We estimate the neutrino fluxes and interaction rates, describe the FASER$\nu$ detector, and analyze the characteristics of the signals and primary backgrounds. For an integrated luminosity of $150~\text {fb}^{-1}$ to be collected during Run 3 of the 14 TeV LHC in 2021–23, approximately 1300 electron neutrinos, 20,000 muon neutrinos, and 20 tau neutrinos will interact in FASER$\nu$, with mean energies of 600 GeV to 1 TeV. With such rates and energies, FASER will measure neutrino cross sections at energies where they are currently unconstrained, will bound models of forward particle production, and could open a new window on physics beyond the standard model.Neutrinos are copiously produced at particle colliders, but no collider neutrino has ever been detected. Colliders, and particularly hadron colliders, produce both neutrinos and anti-neutrinos of all flavors at very high energies, and they are therefore highly complementary to those from other sources. FASER, the recently approved Forward Search Experiment at the Large Hadron Collider, is ideally located to provide the first detection and study of collider neutrinos. We investigate the prospects for neutrino studies of a proposed component of FASER, FASER$\nu$, a 25cm x 25cm x 1.35m emulsion detector to be placed directly in front of the FASER spectrometer in tunnel TI12. FASER$\nu$ consists of 1000 layers of emulsion films interleaved with 1-mm-thick tungsten plates, with a total tungsten target mass of 1.2 tons. We estimate the neutrino fluxes and interaction rates at FASER$\nu$, describe the FASER$\nu$ detector, and analyze the characteristics of the signals and primary backgrounds. For an integrated luminosity of 150 fb$^{-1}$ to be collected during Run 3 of the 14 TeV Large Hadron Collider from 2021-23, and assuming standard model cross sections, approximately 1300 electron neutrinos, 20,000 muon neutrinos, and 20 tau neutrinos will interact in FASER$\nu$, with mean energies of 600 GeV to 1 TeV, depending on the flavor. With such rates and energies, FASER will measure neutrino cross sections at energies where they are currently unconstrained, will bound models of forward particle production, and could open a new window on physics beyond the standard model

Technical Proposal: FASERnu

FASERnu is a proposed small and inexpensive emulsion detector designed to detect collider neutrinos for the first time and study their properties. FASERnu will be located directly in front of FASER, 480 m from the ATLAS interaction point along the beam collision axis in the unused service tunnel TI12. From 2021-23 during Run 3 of the 14 TeV LHC, roughly 1,300 $\nu_e$, 20,000 $\nu_{\mu}$, and 20 $\nu_{\tau}$ will interact in FASERnu with TeV-scale energies. With the ability to observe these interactions, reconstruct their energies, and distinguish flavors, FASERnu will probe the production, propagation, and interactions of neutrinos at the highest man-made energies ever recorded. The FASERnu detector will be composed of 1000 emulsion layers interleaved with tungsten plates. The total volume of the emulsion and tungsten is $25cm \times 25cm \times 1.35m$, and the tungsten target mass is 1.2 tonnes. From 2021-23, 7 sets of emulsion layers will be installed, with replacement roughly every $20-50~fb^{-1}$ in planned Technical Stops. In this document, we summarize FASERnu's physics goals and discuss the estimates of neutrino flux and interaction rates. We then describe the FASERnu detector in detail, including plans for assembly, transport, installation, and emulsion replacement, and procedures for emulsion readout and analyzing the data. We close with cost estimates for the detector components and infrastructure work and a timeline for the experiment.FASERnu is a proposed small and inexpensive emulsion detector designed to detect collider neutrinos for the first time and study their properties. FASERnu will be located directly in front of FASER, 480 m from the ATLAS interaction point along the beam collision axis in the unused service tunnel TI12. From 2021-23 during Run 3 of the 14 TeV LHC, roughly 1,300 electron neutrinos, 20,000 muon neutrinos, and 20 tau neutrinos will interact in FASERnu with TeV-scale energies. With the ability to observe these interactions, reconstruct their energies, and distinguish flavors, FASERnu will probe the production, propagation, and interactions of neutrinos at the highest human-made energies ever recorded. The FASERnu detector will be composed of 1000 emulsion layers interleaved with tungsten plates. The total volume of the emulsion and tungsten is 25cm x 25cm x 1.35m, and the tungsten target mass is 1.2 tonnes. From 2021-23, 7 sets of emulsion layers will be installed, with replacement roughly every 20-50 1/fb in planned Technical Stops. In this document, we summarize FASERnu's physics goals and discuss the estimates of neutrino flux and interaction rates. We then describe the FASERnu detector in detail, including plans for assembly, transport, installation, and emulsion replacement, and procedures for emulsion readout and analyzing the data. We close with cost estimates for the detector components and infrastructure work and a timeline for the experiment

Technical Proposal: FASERnu

FASERnu is a proposed small and inexpensive emulsion detector designed to detect collider neutrinos for the first time and study their properties. FASERnu will be located directly in front of FASER, 480 m from the ATLAS interaction point along the beam collision axis in the unused service tunnel TI12. From 2021-23 during Run 3 of the 14 TeV LHC, roughly 1,300 electron neutrinos, 20,000 muon neutrinos, and 20 tau neutrinos will interact in FASERnu with TeV-scale energies. With the ability to observe these interactions, reconstruct their energies, and distinguish flavors, FASERnu will probe the production, propagation, and interactions of neutrinos at the highest human-made energies ever recorded. The FASERnu detector will be composed of 1000 emulsion layers interleaved with tungsten plates. The total volume of the emulsion and tungsten is 25cm x 25cm x 1.35m, and the tungsten target mass is 1.2 tonnes. From 2021-23, 7 sets of emulsion layers will be installed, with replacement roughly every 20-50 1/fb in planned Technical Stops. In this document, we summarize FASERnu's physics goals and discuss the estimates of neutrino flux and interaction rates. We then describe the FASERnu detector in detail, including plans for assembly, transport, installation, and emulsion replacement, and procedures for emulsion readout and analyzing the data. We close with cost estimates for the detector components and infrastructure work and a timeline for the experiment